J. Sträub

<i>APC</i> mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”

Andrew Rowan, H. Lamlum, Mohammad Ilyas et al. · Proceedings of the National Academy of Sciences · 2000 · 505 citations

Medicine, Genetics, Oncology +17

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

Élena Elez, Ilona Kocáková, Thomas Höhler et al. · Annals of Oncology · 2014 · 119 citations

Medicine, Oncology, Pharmacology +13

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

Johan Vansteenkiste, Fabrice Barlési, Cornelius F. Waller et al. · Annals of Oncology · 2015 · 69 citations · Full text

Medicine, Oncology, Pharmacology +16

Genetic Characterization and High Efficiency Photosynthesis of an Aurea Mutant of Tobacco

Keiichiro Okabe, Georg H. Schmid, J. Sträub · PLANT PHYSIOLOGY · 1977 · 46 citations · Full text

Life Sciences, Plant Biology, Plant Sciences +9

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

James Chih‐Hsin Yang, Barbara Ellers‐Lenz, J. Sträub et al. · Annals of Oncology · 2019 · 15 citations · Full text

Medicine, Oncology, Pharmacology +15